Mutation as a Toxicological Endpoint for Regulatory Decision-Making

被引:44
|
作者
Heflich, Robert H. [1 ]
Johnson, George E. [2 ]
Zeller, Andreas [3 ]
Marchetti, Francesco [4 ]
Douglas, George R. [4 ]
Witt, Kristine L. [5 ]
Gollapudi, B. Bhaskar [6 ]
White, Paul A. [4 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[2] Swansea Univ, Swansea, W Glam, Wales
[3] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland
[4] Hlth Canada, Environm Hlth Sci & Res Bur, Ottawa, ON, Canada
[5] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA
[6] Exponent Inc, Alexandria, VA USA
关键词
germ cell mutation; somatic cell mutation; somatic mosaicism; point of departure; error-corrected next-generation sequencing; GENETIC TOXICOLOGY; SOMATIC MOSAICISM; MOUSE; GENOTOXICITY; TOXICITY; EXPOSURE; LOCUS; DNA; CHEMICALS; RADIATION;
D O I
10.1002/em.22338
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Mutations induced in somatic cells and germ cells are responsible for a variety of human diseases, and mutation per se has been considered an adverse health concern since the early part of the 20th Century. Although in vitro and in vivo somatic cell mutation data are most commonly used by regulatory agencies for hazard identification, that is, determining whether or not a substance is a potential mutagen and carcinogen, quantitative mutagenicity dose-response data are being used increasingly for risk assessments. Efforts are currently underway to both improve the measurement of mutations and to refine the computational methods used for evaluating mutation data. We recommend continuing the development of these approaches with the objective of establishing consensus regarding the value of including the quantitative analysis of mutation per se as a required endpoint for comprehensive assessments of toxicological risk. Environ. Mol. Mutagen. 2019. (c) 2019 Wiley Periodicals, Inc.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 50 条
  • [1] Genetic Toxicity as a Bone Fide Toxicological Endpoint for Regulatory Evaluations and Decision Making.
    Heflich, R.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2018, 59 : 52 - 52
  • [2] REFORMING REGULATORY DECISION-MAKING - THE REGULATORY BUDGET
    THOMPSON, F
    JONES, LR
    SLOAN MANAGEMENT REVIEW, 1981, 22 (02): : 53 - 61
  • [3] Impact of PDUFA on regulatory decision-making
    Hay, Michael
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (08) : 585 - 585
  • [4] Impact of PDUFA on regulatory decision-making
    Michael Hay
    Nature Reviews Drug Discovery, 2010, 9 : 585 - 585
  • [5] PROCESS AND OUTCOME IN REGULATORY DECISION-MAKING
    MAJONE, G
    AMERICAN BEHAVIORAL SCIENTIST, 1979, 22 (05) : 561 - 583
  • [6] TECHNICAL BASIS FOR REGULATORY DECISION-MAKING
    THRODAHL, MC
    CHEMISTRY & INDUSTRY, 1978, (07) : 221 - 223
  • [7] RISK ASSESSMENT AND REGULATORY DECISION-MAKING
    MUNRO, IC
    KREWSKI, DR
    FOOD AND COSMETICS TOXICOLOGY, 1981, 19 (05): : 549 - 560
  • [8] Evidence-based tools in toxicological decision-making
    Griesinger, C.
    Hoffmann, S.
    Kinsner, A.
    Coecke, S.
    Hartung, T.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2009, 28 (2-3) : 155 - 155
  • [9] THE IMPORTANCE OF THE OVERALL SURVIVAL ENDPOINT IN EU HTA DECISION-MAKING
    Bustamante, M. M. D.
    Oshinowo, B.
    Subbotina, E.
    McGahan, S.
    VALUE IN HEALTH, 2019, 22 : S99 - S99
  • [10] Regulatory focus and interdependent economic decision-making
    Gu, Jun
    Bohns, Vanessa K.
    Leonardelli, Geoffrey J.
    JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY, 2013, 49 (04) : 692 - 698